(2S,3R,4R,5S,6R)-2-[3-[(4-ethanimidoylphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3R,4R,5S,6R)-2-[3-[(4-ethanimidoylphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₁H₂₅NO₅
• 分子量: 371.4
• InChiKey: LMHRQJAGPOQWBG-ADAARDCZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  114
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• NOVEL SGLT INHIBITORS
  申请人：Jain Rajesh

  公开号：US20140228303A1

  公开（公告）日：2014-08-14

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

  本发明涉及公式I的新化合物，它们的药学可接受衍生物、互变异构体、同分异构体、多晶形、前药、代谢物、盐或其溶剂。本发明还涉及合成公式I的新化合物、其药学可接受衍生物、互变异构体、同分异构体、多晶形、前药、代谢物、盐或其溶剂的过程。本发明还提供了包含公式I的新化合物的药物组合物和通过抑制钠葡萄糖协同转运体-2（SGLT-2）调节或规范的一种或多种疾病或疾病状态的治疗或预防方法。